Catch­ing up with Keytru­da, Re­gen­eron scores front­line NSCLC ap­proval for Lib­tayo/chemo com­bo

Re­gen­eron’s Lib­tayo has made it in­to the ex­clu­sive club of PD-(L) in­hibitors ap­proved, in com­bi­na­tion with chemother­a­py, as a front­line treat­ment for a broad swath of lung can­cer pa­tients.

Based on Phase III over­all sur­vival da­ta, the FDA grant­ed Lib­tayo an ap­proval for the first-line treat­ment of adult pa­tients with ad­vanced non-small cell lung can­cer with no EGFR, ALK or ROS1 aber­ra­tions.

“Lib­tayo is now ap­proved for ex­tend­ing the sur­vival of pa­tients with ad­vanced non-small cell lung can­cer as both a monother­a­py in high PD-L1 ex­pres­sors and in com­bi­na­tion with chemother­a­py ir­re­spec­tive of PD-L1 ex­pres­sion lev­els, achiev­ing a high bar that has on­ly been met by one oth­er PD-1 tar­get­ing agent,” said Is­rael Lowy, SVP, trans­la­tion­al and clin­i­cal sci­ences, on­col­o­gy at Re­gen­eron.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters